Inicio | Área Farmacias | Bibliografía

Bibliografía

1 Heurteaux C, Gandin C, Borsotto M, Widmann C, Brau F, Lhuillier M, et al. Neuroprotective and neuroproliferative activities of NeuroAiD™ (MLC601, MLC901), a Chinese medicine, in vitro and in vivo. Neuropharmacology. 2010;58(7):987-1001.


2 Quintard H, Borsotto M, Veyssiere J, Gandin C, Labbal F, Widmann C, et al. MLC901, a traditional Chinese medicine protects the brain against global ischemia. Neuropharmacology. 2011;61(4):622-31.


3 Moha Ou Maati H, Borsotto M, Chatelain F, Widmann C, Lazdunski M, Heurteaux C. Activation of ATP-sensitive potassium channels as an element of the neuroprotective effects of the traditional Chinese medicine MLC901 against oxygen glucose deprivation. Neuropharmacology. 2012;63(4):692-700.


4 Heurteaux C, Widmann C, Moha ou Maati H, Quintard H, Gandin C, Borsotto M, et al. NeuroAiD™: properties for neuroprotection and neurorepair. Cerebrovasc Dis. 2013; 35 Suppl 1:1-7.


5 Chen C, Venketasubramanian N, Gan RN, Lambert C, Picard D, Chan BP, et al. Danqi Piantan Jiaonang, a traditional Chinese medicine, in post stroke recovery. Stroke. 2009; 40: 859-63.


6 Harandi AA, Abolfazli R, Hatemian A, Ghragozlee K, Ghaffar-Pour M, Karimi M, et al. Safety and effi cacy of MLC601 in Iranian patients after stroke: a double-blind, placebo-controlled clinical trial. Stroke Res Treat. 2011;2011:721613.


7 Shahripour RB, Shamsaei G, Pakdaman H, Majdinasab N, Nejad EM, Sajedi SA, et al. The effect of NeuroAiD™ (MLC601) on cerebral blood fl ow velocity in subjects' post brain infarct in the middle cerebral artery territory. Eur J Intern Med. 2011;22(5):509-13.


8 Siddiqui FJ, Venketasubramanian N, Chan ES, Chen C. Effi cacy and safety of MLC601 (NeuroAiD™), a traditional Chinese medicine, in postroke recovery: a systematic review. Cerebrovasc Dis. 2013;35 Suppl 1:8-17.


9 Chen CL, Young SH, Gan HH, Singh R, Lao AY, Baroque AC 2nd, et al. Chinese medicine NeuroAiD™ effi cacy on stroke recovery: a double-blind, placebo-controlled, randomized study. Stroke. 2013;44(8):2093-100.


10 Chen CL, Venketasubramanian N, Lee CF, Wong KS, Bousser MG; CHIMES Study Investigators. Effects of MLC601 on early vascular events in patients after stroke: The CHIMES study. Stroke, 2013;44(12):3580-3.


11 Gan R, Lambert C, Lianting J, Chan ES, Venketasubramanian N, Chen C, et al. Danqi Piantan Jiaonang does not modify hemostasis, hematology, and biochemistry in normal subjects and stroke patients. Cerebrovasc Dis. 2008;25(5):450-6.


12 Young SH, Zhao Y, Koh A, Singh R, Chan BP, Chang HM, et al. Safety profi le of MLC601 (NeuroAiD™) in acute ischemic stroke patients: a Singaporean substudy of the Chinese medicine NeuroAiD™ efficacy on stroke recovery study. Cerebrovasc Dis. 2010;30(1):1-6.


13 Shahripour RB, Hemati A, Maleki AH. Randomized trial to assess the long-term safety of NeuroAiD™ among caucasian patients with acute ischemic stroke. Chin J Integr Med. 2014 Apr 2. [Epub ahead of print].